Revenue by Product

9 Months Ended

Sep. 30, 2019

Segment Reporting [Abstract]

Revenue by Product

Revenue by Product 

The Company has determined that it operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer based technology. The Company’s Chief Operating Decision Maker is the CEO. The CEO reviews profit and loss information on a consolidated basis to assess performance and make overall operating decisions as well as resource allocations. All products are included in one segment because the Company’s products have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment. 

The following table presents a summary of total revenues by these products: 

	Three Months Ended September 30,					Nine Months Ended September 30,
Revenues by Product:	2019			2018		2019		2018
Bloxiverz	$	1,466		$	3,656	$	6,392	$	16,691
Vazculep	8,786			8,759		27,669		33,097
Akovaz	4,208			5,991		13,946		28,083
Other	(231		)	1,420		213		4,232
Total product sales	14,229			19,826		48,220		82,103
License revenue	—			—		—		246
Total revenues	$	14,229		$	19,826	$	48,220	$	82,349